Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Encyclopedia, Wikipedia.
AVIAudio Video Interleave (multimedia container format)
AVIAutomatic Vehicle Identification
AVIAudio Visual, Inc. (various locations)
AVIAortic Valve Insufficiency
AVIAudio Video Interleaving
AVIAudio Video Integration
AVIAustralian Volunteers International (Fitzroy, Victoria, Australia)
AVIActual Value Initiative (Philadelphia, PA)
AVIAdvitech Inc. (Quebec, Quebec, Canada; stock symbol)
AVIAutomated Vehicle Identification
AVIAuditory-Verbal International
AVIAssociation for Veterinary Informatics
AVIAdvanced Visual Interface
AVIArt Vivant (French: Living Art)
AVIAdd Value International (e-business; Canada)
AVIAvionics Integration
AVIAmerican Veterans Institute (Tipp City, OH)
AVIAdopted Vietnamese International
AVIAdvanced Vehicle Identification
AVIArk Valley Interurban (trolley; Kansas)
AVIAnalog VHDL International (industry group)
AVIAluminium Véranda Industrie (French: Veranda Aluminium Industry; Asnières sur Oise, France)
AVIAbdominal Volume Index
AVIArabian Vermiculite Industries (Saudi Arabia manufacturer of fireproofing products)
AVIAudio Video Interactive, Ltd. (interactive audiovisual services)
AVIAirborne Vehicle Identification
AVIArmy Veterinary Inspector (typically, a military food inspector)
AVIAustralian Veterinarians in Industry (Australian Veterinary Association)
AVIAortic Valve Area Index
AVIAviation Restructure Initiative (US Army)
AVIAudio-Visual Isomorphism
AVIAudio Visual Integration, Inc (Fort Wayne, IN)
References in periodicals archive ?
AVI has the manufacturing capacity to produce clinical-grade NEUGENE antiviral therapeutics, targeting viral pathogens, for a limited number of patients within days.
AVI has shown in a previous Phase II clinical study that its drug AVI-4126 (Resten-NG([R])), also targeting the c-myc gene, reduced the restenosis rate after balloon angioplasty and stent placement by approximately 75 percent.
Based on these data, AVI has initiated a protocol modification to increase treatment duration.
The first presentation, titled "Inhibition of Several Subtypes of Influenza A Virus with Antisense Morpholino Oligomers," was presented by AVI collaborators from Oregon State University and included data from collaborators at the Massachusetts Institute of Technology; the Public Health Agency of Canada in Winnipeg; and Mahidol University in Bangkok, Thailand.